Please login to the form below
Eloxatin
This page shows the latest Eloxatin news and features for those working in and with pharma, biotech and healthcare.
Sanofi predicts return to growth in second half
Sanofi is still weathering the effects of patent losses in 2012 for antiplatelet drug Plavix (clopidogrel), Avapro (irbesartan) for high blood pressure and cancer therapy Eloxatin (oxaliplatin) which collectively lost
Latest news
-
Sanofi predicts end of patent cliff in 2013
cancer stalwart Eloxatin (oxaliplatinl) was down more than 80 per cent to 68m.
-
Sanofi receives EU approvals for diabetes and cancer drugs
has progressed after previous treatment with a regimen including oxaliplatin (marketed by Sanofi as Eloxatin).
-
Sanofi wins Eloxatin patent case
A US district court has ruled in favour of Sanofi retaining marketing exclusivity for colorectal cancer treatment Eloxatin until August 2012 following a patent challenge from Sun Pharmaceuticals. ... The company said it still sees Eloxatin as an
-
S-A profits reach €2.49bn for Q2
These strong performers helped counter falling sales in other divisions of the company, including chemotherapy medicine Eloxatin (oxaliplatin), for which sales fell 73.4 per cent for the quarter, and heart
-
Sanofi-aventis looking at $20bn acquisition
S-A is seeking acquisitions to help offset sales lost from the launch of generic versions of Eloxatin (oxaliplatin) and Plavix (clopidogrel).
More from news
Approximately 0 fully matching, plus 16 partially matching documents found.
Latest appointments
-
AP Pharma overhauls senior management team
He added: “Rob brings deep experience in the commercialisation of oncology drugs and was responsible for the launch of two products, Nexavar and Eloxatin, that each achieved sales of more than
-
Bayer’s former oncology head Robert Rosen joins AP Pharma
Prior to joining Bayer, Rosen was VP of the oncology business unit at Sanofi-Synthèlabo, where he helped develop Sanofi's cancer footprint in the US with the launch of Eloxatin
-
Former Bayer oncology head Robert Rosen joins AP Pharma's board
Prior to his time at Bayer, Rosen spent three years at Sanofi-Synthelabo as VP of its oncology business unit, and was responsobile for the launch of Eloxatin (oxaliplatin) for colon
More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.
Subscribe to our email news alerts
-
Pharmacovigilance Project Lead
- Highly competitive salary
- Strategy Director - Healthcare Advertising
- Highly competitive salary
-
Technical Sales Representative
- Highly competitive salary
-
Pharmacovigilance Manager
- Highly competitive salary
-
Omnichannel Account Director
- £55,000 - £65,000 yearly
- Early Access Program - Regulatory Affairs (EAP-RA)
- Highly competitive salary
-
Senior Medical Writer
- Highly competitive salary
- Associate Director - Global Healthcare Consulting
- Highly competitive salary
- Novo Nordisk suspended from ABPI over ‘serious’ code of practice breaches
- Roche and Eli Lilly to collaborate on Alzheimer’s disease blood test
- MHRA to introduce new UK clinical trials framework
- Pfizer pays Royalty Pharma $475m following US approval of migraine nasal spray
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- 2023 PM Society Awards – winners announced
- AstraZeneca/MSD’s Lynparza combination approved in UK for prostate cancer
- WHO report highlights impact of COVID-19 pandemic on non-communicable diseases
- Critical success factors and the increasing value of rare disease clinical trials
- Quantum Computing, Artificial Intelligence, & Machine Learning for Drug Discovery
- Novo Nordisk and Dewpoint partner on insulin resistance drug candidates
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- Locus Biosciences announces first patient treated in urinary tract infection trial
- GSK reports positive phase 3 results for five-in-one meningococcal vaccine candidate
- Kite reports positive three-year results for CAR T-cell therapy in rare blood cancer
- Results for Astellas’ non-hormonal menopause drug published in The Lancet
- Ketchum appoints Conor Nash as global chief financial officer and chief operating officer
PMHub
Life Healthcare Communications
Life is a creative communications agency offering multi-channel solutions for the healthcare industry. We use a storytelling approach to turn...
Latest intelligence
- Rare diseases: not so rare after all
- The brave new world addressing rare diseases – a way ahead to better and more inclusive treatment...
- Webinar: Evolving Patient Journeys - How to generate deeper insights in a changing healthcare landscape
- Register now for part one in a series, Evolving Patient Journeys, in which our experts look at the main ways in which the patient journey has evolved in recent years....
- DIGITAL EXPERIENCES: LEARNINGS FROM OUTSIDE PHARMA
- It’s long been the case that pharma lags behind other industries when it comes to digital adoption and engagement. So, what can we learn from these other industries, and how...
